{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:25:09Z","timestamp":1785835509721,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"novartis pharma","doi-asserted-by":"publisher","award":["novartis pharma"],"award-info":[{"award-number":["novartis pharma"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-scale, real-world evidence in multi-centre settings is still needed to confirm these results. Erenumab patient profiles outside clinical trials and physicians\u2019 treatment patterns, as well as data from patients treated in Germany, a severely impacted population, are not published yet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>TELESCOPE was a multi-centre survey gathering real-world data from 45 German headache centres between July 2019 and December 2019. The project consisted of two parts. In the first part, treating physicians shared their experiences on current erenumab treatment with regard to patient profiles, treatment patterns and treatment responses. In the second part, a retrospective chart review was conducted of 542 migraine patients treated with erenumab for at least three months. Treatment responses focused on various aspects of patients\u2019 quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis of 542 patients\u2019 charts revealed that three-month treatment with erenumab significantly reduced monthly headaches, migraine and acute medication days. Furthermore, headache intensity and frequency were reduced in over 75\u2009% and accompanying aura in 35\u2009% of patients. The clinical global impression scale revealed a general improvement in 91\u2009% of patients. According to the treating physicians\u2019 professional judgement, 83\u2009% of patients responded to erenumab and 80\u2009% were satisfied with the treatment. Physicians evaluated restricted quality of life, the number of monthly migraine days and previous, prophylactic treatments as the main components of the current patient profile for monoclonal antibody recipients. Based on the assessment of physicians, erenumab reduced migraine symptoms in 65\u2009% and increased quality of life in more than 75\u2009% of their patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TELESCOPE confirms positive treatment responses with erenumab shown in clinical trials in a real-world multi-centre setting. The results show consistently positive experiences of physicians utilizing erenumab in clinical practice and underline that therapy with this monoclonal antibody is effective in migraine patients, particular in those, who have failed several prophylactic therapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-021-01344-1","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T19:02:49Z","timestamp":1636225369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany"],"prefix":"10.1186","volume":"22","author":[{"given":"Andreas","family":"Straube","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Stude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-6227","authenticated-orcid":false,"given":"Mirja","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"issue":"11","key":"1344_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"1344_CR2","doi-asserted-by":"publisher","unstructured":"Porst M, Wengler A, Leddin J, Neuh\u00e4user H, Katsarava Z, von der Lippe E et al (2020) Migr\u00e4ne und Spannungskopfschmerz in Deutschland. Pr\u00e4valenz und Erkrankungsschwere im Rahmen der Krankheitslast-Studie BURDEN 2020. J Health Monit 5(Special Issue 6). https:\/\/doi.org\/10.25646\/6990","DOI":"10.25646\/6990"},{"issue":"9","key":"1344_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102420919098","volume":"40","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Evers S (2020) International classification of headache disorders - ICHD-4 alpha. Cephalalgia 40(9):887\u2013888. https:\/\/doi.org\/10.1177\/0333102420919098","journal-title":"Cephalalgia"},{"key":"1344_CR4","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1-211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"1344_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V et al (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20(1):57. https:\/\/doi.org\/10.1186\/s10194-018-0899-2","journal-title":"J Headache Pain"},{"issue":"5","key":"1344_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"key":"1344_CR7","doi-asserted-by":"publisher","unstructured":"Edvinsson L, Mulder H, Goadsby PJ, Uddman R (1998) Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst 70(1\u20132):15\u201322. https:\/\/doi.org\/10.1016\/s0165-1838(98)00033-2","DOI":"10.1016\/s0165-1838(98)00033-2"},{"issue":"Suppl 1","key":"1344_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10072-019-03769-8","volume":"40","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ (2019) CGRP and headache: a brief review. Neurol Sci 40(Suppl 1):99\u2013105. https:\/\/doi.org\/10.1007\/s10072-019-03769-8","journal-title":"Neurol Sci"},{"issue":"6","key":"1344_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"22","key":"1344_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"6","key":"1344_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/s1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"10161","key":"1344_CR12","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/s0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287. https:\/\/doi.org\/10.1016\/s0140-6736(18)32534-0","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1344_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","volume":"40","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci 40(Suppl 1):177\u2013179. https:\/\/doi.org\/10.1007\/s10072-019-03839-x","journal-title":"Neurol Sci"},{"issue":"1","key":"1344_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","journal-title":"J Headache Pain"},{"key":"1344_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417. https:\/\/doi.org\/10.3389\/fneur.2020.00417","journal-title":"Front Neurol"},{"issue":"1","key":"1344_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21(1):69. https:\/\/doi.org\/10.1186\/s10194-020-01143-0","journal-title":"J Headache Pain"},{"issue":"1","key":"1344_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"issue":"1","key":"1344_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84. https:\/\/doi.org\/10.1186\/s10194-020-01151-0","journal-title":"J Headache Pain"},{"key":"1344_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04658-1","author":"U Pensato","year":"2020","unstructured":"Pensato U, Favoni V, Pascazio A, Benini M, Asioli GM, Merli E et al (2020) Erenumab efficacy in highly resistant chronic migraine: a real-life study. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04658-1","journal-title":"Neurol Sci"},{"key":"1344_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04677-y","author":"A Ranieri","year":"2020","unstructured":"Ranieri A, Alfieri G, Napolitano M, Servillo G, Candelaresi P, Di Iorio W et al (2020) One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04677-y","journal-title":"Neurol Sci"},{"issue":"1","key":"1344_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S (2021) Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain 22(1):5. https:\/\/doi.org\/10.1186\/s10194-020-01214-2","journal-title":"J Headache Pain"},{"issue":"10","key":"1344_CR22","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache 60(10):2555\u20132562. https:\/\/doi.org\/10.1111\/head.13968","journal-title":"Headache"},{"issue":"Suppl 2","key":"1344_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10072-020-04665-2","volume":"41","author":"C Disco","year":"2020","unstructured":"Disco C, Billo G, De Boni A, De Luca C, Perini F (2020) Efficacy of erenumab 70\u00a0mg in chronic migraine: Vicenza experience. Neurol Sci 41(Suppl 2):479\u2013480. https:\/\/doi.org\/10.1007\/s10072-020-04665-2","journal-title":"Neurol Sci"},{"issue":"9","key":"1344_CR24","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60(9):2014\u20132025. https:\/\/doi.org\/10.1111\/head.13951","journal-title":"Headache"},{"issue":"Suppl 2","key":"1344_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","volume":"41","author":"F Schiano di Cola","year":"2020","unstructured":"Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U et al (2020) Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 41(Suppl 2):489\u2013490. https:\/\/doi.org\/10.1007\/s10072-020-04670-5","journal-title":"Neurol Sci"},{"issue":"Suppl 2","key":"1344_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10072-020-04667-0","volume":"41","author":"E Matteo","year":"2020","unstructured":"Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM et al (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. Neurol Sci 41(Suppl 2):483\u2013484. https:\/\/doi.org\/10.1007\/s10072-020-04667-0","journal-title":"Neurol Sci"},{"key":"1344_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00264-x","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. https:\/\/doi.org\/10.1007\/s40122-021-00264-x","journal-title":"Pain Ther"},{"issue":"6","key":"1344_CR28","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s12325-021-01677-y","volume":"38","author":"J Fang","year":"2021","unstructured":"Fang J, Korrer S, Johnson JC, Cheadle MA, Shah R, Ferraris ML et al (2021) Real-world trends in characteristics of patients with migraine newly initiated on erenumab in the USA: a retrospective analysis. Adv Ther 38(6):2921\u20132934. https:\/\/doi.org\/10.1007\/s12325-021-01677-y","journal-title":"Adv Ther"},{"issue":"13","key":"1344_CR29","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511\u20131522. https:\/\/doi.org\/10.1177\/0333102420946725","journal-title":"Cephalalgia"},{"issue":"1","key":"1344_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G et al (2020) Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain 21(1):102. https:\/\/doi.org\/10.1186\/s10194-020-01171-w","journal-title":"J Headache Pain"},{"key":"1344_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10523-8","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-021-10523-8","journal-title":"J Neurol"},{"key":"1344_CR32","unstructured":"German Federal Joint Committee (Gemeinsamer Bundesausschuss=GBA). Erenumab: resolution and justification. Available online at: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/411\/#english.\u00a0Assessed 19\u00a0Feb\u00a02021"},{"key":"1344_CR33","unstructured":"Report of the Association of Private Health Insurers in Germany. Avaiable online at https:\/\/www.pkv.de\/fileadmin\/user_upload\/PKV\/c_Verband\/PDF\/2020-12_PKV-Zahlenbericht_2019.pdf.\u00a0Assessed 19\u00a0Feb\u00a02021"},{"key":"1344_CR34","doi-asserted-by":"publisher","unstructured":"Diener H-C, Holle-Lee D, N\u00e4gel S, Dresler T, Gaul C, G\u00f6bel H et al (2019) Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci 3(1). https:\/\/doi.org\/10.1177\/2514183x18823377","DOI":"10.1177\/2514183x18823377"},{"key":"1344_CR35","unstructured":"German Society of Neurology (Deutsche Gesellschaft Neurologie = DGP). Addendum to guideline 030\/057 therapy of migraine attacks and prophylaxis. Available at: https:\/\/www.awmf.org\/fileadmin\/user_upload\/Leitlinien\/030_D_Ges_fuer_Neurologie\/030-057addendum_S1_Migraene-Therapie-Prophylaxe_2020-02-verlaengert.pdf.Assessed 19\u00a0Feb\u00a02021"},{"issue":"1","key":"1344_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F et al (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20(1):99. https:\/\/doi.org\/10.1186\/s10194-019-1054-4","journal-title":"J Headache Pain"},{"issue":"6","key":"1344_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein SD et al (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40(6):543\u2013553. https:\/\/doi.org\/10.1177\/0333102420912726","journal-title":"Cephalalgia"},{"issue":"1","key":"1344_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","volume":"19","author":"T Schwedt","year":"2018","unstructured":"Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G et al (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19(1):92. https:\/\/doi.org\/10.1186\/s10194-018-0923-6","journal-title":"J Headache Pain"},{"issue":"1","key":"1344_CR39","doi-asserted-by":"publisher","first-page":"e13029","DOI":"10.2196\/13029","volume":"9","author":"LK Volpicelli","year":"2020","unstructured":"Volpicelli LK, Robertson C, Bhowmick A, Herbert LB (2020) Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: a self-reported survey. Interact J Med Res 9(1):e13029. https:\/\/doi.org\/10.2196\/13029","journal-title":"Interact J Med Res"},{"issue":"1","key":"1344_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-021-01215-9","volume":"22","author":"M Ament","year":"2021","unstructured":"Ament M, Day K, Stauffer VL, Skljarevski V, Rettiganti M, Pearlman E et al (2021) Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain 22(1):6. https:\/\/doi.org\/10.1186\/s10194-021-01215-9","journal-title":"J Headache Pain"},{"issue":"1","key":"1344_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC et al (2018) My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain 19(1):115. https:\/\/doi.org\/10.1186\/s10194-018-0946-z","journal-title":"J Headache Pain"},{"issue":"11","key":"1344_CR42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2165\/11315330-000000000-00000","volume":"29","author":"M Guidotti","year":"2009","unstructured":"Guidotti M, Ravasio R (2009) Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world setting. Clin Drug Investig 29(11):693\u2013702. https:\/\/doi.org\/10.2165\/11315330-000000000-00000","journal-title":"Clin Drug Investig"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01344-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T19:03:20Z","timestamp":1636225400000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01344-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01344-1","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the research format, this study was exempted from ethics committee review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS received honoraria for educational talks and advisory boards from Allergan Lilly, Novartis, Sanofi and Teva.PS received honoraria for advisory boards from Novartis, TEVA, Lilly and Hormosan.CG received honoraria for consulting and lectures within the past three years from Allergan Pharma, Lilly, Novartis, Hormosan, Gr\u00fcnenthal, Sanofi-Aventis, Weber & Weber, Lundbeck and TEVA. He does not hold any stocks of pharmaceutical companies. He is honorary secretary of the German Migraine and Headache Society.KS is employed at Novartis Pharma GmbH, Nuremberg, Germany, the sponsor.MK is employed at Novartis Pharma AG, Basel, Switzerland, the sponsor.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}